Athelas is developing technology to allow blood testing for neutrophils, lymphocytes, platelets, WBCs, morphology, and cell activation from less blood than is currently required. Athelas uses Computer Vision instead of traditional coulter counting or flow based cytometry. The company is based in Mountain View, CA.
The Athelas One for analysis of white blood cell and neutrophil percent is FDA approved for point-of-care indications. The device uses a finger prick of blood and completes analysis in minutes. The Athelas app for Android and iOS is used to deliver blood test results. The device is marketed for oncologists for monitoring oncology patients, life sciences researchers and for patients. The device can also be used to test for viral or bacterial infection and possibly predict cardiac arrest.
Exclusive Canadian rights for the Athelas One device was in-licensed by pharmaceutical company HLS Therapeutics. Athelas One is designed to enhance and simplify the mandatory safety blood monitoring process for patients prescribed CLOZARIL (clozapine) which is approved for Treatment Resistant Schizophrenia (TRS). As of March 2019, HLS had exclusive right to the device in the field of schizophrenia. Health Canada granted the Athelas One device to be marketed as CSAN® PRONTO™ and become part of the Clozaril Support and Assistance Network (CSAN) available to Canadian Institutions and healthcare providers.
The device will be used for safety blood monitoring in treatment of Treatment Resistant Schizophrenia with clozapine.
Clinical third party validation of Athelas One
Nikhil Basu Trivedi